FindTrial
Sign In

Islets beta-cell function and usefulness of sulfonylureas in glycemic control in type 2 diabetic patients with sulfonylurea failure.

Islets beta-cell function and usefulness of sulfonylureas in glycemic control in type 2 diabetic patients with sulfonylurea failure.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
TCTR
Registry ID
TCTR20170525001
Enrollment
Unknown
Registered
2017-05-25
Start date
2008-02-08
Completion date
Unknown
Last updated
2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None Sulfonylurea failure Type 2 DM

Interventions

At the time of recruitment&#44
each patient in SUF group was assessed for body weight&#44
height&#44
body mass index (BMI)&#44
biochemical profile including fasting plasma glucose&#44
A1C&#44
serum blood urea nitrogen&#44
creatinine&#44
AST and ALT levels&#44
anti&#45
glutamic acid decarboxylase 65 (anti&#45
GAD 65) to exclude the possibility of type 1 diabetes&#44
and was assigned to perform standard lifestyle management and fasting capillary blood glucose (CBG) measurement at home every other day throughout the study. After the initial assessment&#44
the patients were assigned to continue maximum dosage of the same SU (Max&#45
SU) and the same types and dosages of other oral hypoglycemic agents for 2 weeks and then were undergone the first 75&#45
gram oral glucose tolerance test&#44
so&#45
called Max&#45
SU OGTT. After finishing the Max&#45
SU OGTT&#44

Sponsors

None
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Type 2 diabetic patients who had sulfonylurea failure. Sulfonylurea failure defined by the presence of hemoglobin A1C levels of >8% for longer than 6 months during treatment with combination of recommended maximum dosages of an SU and metformin.

Exclusion criteria

Exclusion criteria: Currently treated with insulin and dipeptidyl peptidase-4 (DPP-4) inhibitors, glucocorticoid therapy, acute illnesses and infections, serum creatinine levels of >1.5 mg/dL, and serum aspartate transferase (AST) and/or alanine transferase (ALT) levels of >3 times higher than the upper limit of normal ranges, and history of diabetic ketoacidosis or hyperglycemic hyperosmolar non-ketotic state.

Design outcomes

Primary

MeasureTime frame
To examine islets beta-cell function and usefulness of SU in type 2 diabetic patients who could not During taking sulfonulurea and stop taking sulfonylurea Beta cell function and insulin resistance assess by OGTT—

Secondary

MeasureTime frame
None None None—

Countries

Thailand

Contacts

Public ContactTada Kunavisarut

Mahidol University

kunavisarut@gmail.com024197799

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Apr 4, 2026